NEWS

Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...

Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...

Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...

FOR IMMEDIATE RELEASE JAN. 17, 2025   WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...

Washington, DC  – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...

For Immediate Release June 5, 2024 Contact: Lisa Glass 512-695-3569 / lglass@rosscomm.com New Data Reveals Strong Economic Impact of...

The Latest Plan from Some House Democrats to Expand Government Drug Price Controls Will Lead to Further Declines in New Treatments for...

FOR IMMEDIATE RELEASE August 8, 2023 Washington, DC – At a time when preserving America’s leadership in life sciences innovation is...

CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on Patients, Jobs and Cures Latest Announcement...

Washington, DC – A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer,...